The Daily Biotech Pulse: AstraZeneca's vaccine as effective as mRNA shots, Humanigen's Lenzilumab disappoints
The Daily Biotech Pulse: AstraZeneca's vaccine as effective as mRNA shots, Humanigen's Lenzilumab disappoints
生物技术每日脉搏：阿斯利康疫苗与mRNA注射一样有效，Humanigen的lenzilumab令人失望
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是过去24小时生物技术领域的热门发展综述：
Stocks In Focus
关注的股票
Atara Shares Fall After Update On Multiple Sclerosis Trial
Atara股价在多发性硬化症试验更新后下跌
Atara Biotherapeutics(ATRA.US) completed the planned Interim Analysis of the ATA188 Phase 2 study (EMBOLD) in progressive multiple sclerosis patients.
Atara BioTreateutics(ATRA.US)完成了进展性多发性硬化症患者ATA188第二阶段研究(EMBOLD)的中期分析计划。
The analysis' primary focus was on expanded disability status scale (EDSS) improvement at six months and overall safety.
分析的主要焦点是扩展的残疾状况量表(EDSS)在6个月时的改善情况和总体安全性。
The safety monitoring committee believes the six-month interim endpoint may be an inaccurate measure. It recommended continuing the study without sample size adjustment until the final analysis.
安全监测委员会认为，6个月的临时终点可能是一个不准确的衡量标准。它建议继续进行这项研究，不调整样本量，直到最终分析。
The final read-out is planned for October...
最终读数计划在2...
登录免费看全文
登录/注册